
|Articles|November 21, 2017
OmniComm Systems Signs Letter of Intent to Acquire Assets of Algorithm and its Algorics
Advertisement
OmniComm Systems, Inc. and Algorithm, Inc. have signed a letter of intent, under which OmniComm will acquire assets and assume liabilities of Algorics to build upon RBM and data analytics. By combining forces, the companies expect increased operating efficiency, strengthened traction in the risk-based approach solution area, new marketing opportunities, an expanded portfolio of electronic data capture solutions for the clinical trials industry, and will provide OmniComm with access to advanced analytics and algorithms.
Read the full release
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
The Career They Didn't Train For: Rethinking Early-Career Burnout in Clinical Research
2
Breaking the Efficacy Ceiling in IBD and Beyond
3
ACT Brief: Substance Versus Branding in Biotech Support, Site-Level Execution Gaps and Point-of-Care Data, and KCNT1-Targeted Pediatric Epilepsy Program
4
Why Clinical Trial Modernization Fails Without Point-of-Care Data: Q&A with Richard Graham, PhD, TruTechnologies
5



